Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features (Q37982940)

26 August 2017

Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features (English)

1 reference

26 August 2017

Jaime Prat

1

1 reference

26 August 2017

10 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

460

1 reference

26 August 2017

3

1 reference

26 August 2017

237-249

1 reference

https://scigraph.springernature.com/pub.10.1007/s00428-012-1203-5

26 August 2017

0 references

cites work

Colorectal cancer: a multipathway disease

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Ovarian carcinoma pathology and genetics: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Serous carcinogenesis in the fallopian tube: a descriptive classification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Fallopian tube correlates of ovarian serous borderline tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

The genesis and evolution of high-grade serous ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Genetic analysis of the early natural history of epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Low-grade serous carcinomas of the ovary contain very few point mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

A distinct molecular profile associated with mucinous epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Histologic transformation of benign endometriosis to early epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

ARID1A mutations in endometriosis-associated ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Selectivity of chromatin-remodelling cofactors for ligand-activated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Alternate molecular genetic pathways in ovarian carcinomas of common histological types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1203-5

Mutation of the PIK3CA gene in ovarian and breast cancer

21 January 2018

1 reference

12 December 2020

WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma

1 reference

12 December 2020

Frequency of BRCA1 dysfunction in ovarian cancer

1 reference

12 December 2020

Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.

1 reference

12 December 2020

Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants

1 reference

12 December 2020

Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.

1 reference

12 December 2020

Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma.

1 reference

12 December 2020

Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis

1 reference

12 December 2020

Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage

1 reference

12 December 2020

Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation

1 reference

12 December 2020

Summary and discussion of session recommendations

1 reference

12 December 2020

Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'

1 reference

12 December 2020

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

1 reference

12 December 2020

Tubal ligation and risk of ovarian cancer

1 reference

12 December 2020

Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors

1 reference

12 December 2020

Borderline ovarian tumors: key points and workshop summary

1 reference

12 December 2020

K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases

1 reference

12 December 2020

The origin of ovarian cancer—is it getting clearer?

1 reference

12 December 2020

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer

1 reference

12 December 2020

Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary

1 reference

12 December 2020

Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas

1 reference

12 December 2020

Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules

1 reference

12 December 2020

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

1 reference

12 December 2020

Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary

1 reference

12 December 2020

Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential

1 reference

12 December 2020

Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma

1 reference

12 December 2020

Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas.

1 reference

12 December 2020

Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas

1 reference

12 December 2020

Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas

1 reference

12 December 2020

PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters

1 reference

12 December 2020

Grading ovarian serous carcinoma using a two-tier system

1 reference

12 December 2020

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

12 December 2020

Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up

1 reference

12 December 2020

10.1007/S00428-012-1203-5

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22322322